Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003999 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL6003376 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL5433122 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL13823322 | 0.83 | KCNH2 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL20740744 | 0.83 | KCNH2 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL27158028 | 0.83 | KCNH2 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL11472691 | 0.83 | KCNH2 (0.51) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL5440038 | 0.83 | KCNH2 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL11463570 | 0.82 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNH2DRD2 | |
| SCHEMBL6003488 | 0.82 | DRD3 (0.46) | KCNH2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | claimed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | claimed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | SLC6A4 1519/4885SLC6A2 1776/4885SLC6A3 955/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | SLC6A4 44/4885SLC6A2 14/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.